Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Genes with bimodal expression are robust diagnostic targets that define distinct subtypes of epithelial ovarian cancer with different overall survival.

Kernagis DN, Hall AH, Datto MB.

J Mol Diagn. 2012 May-Jun;14(3):214-22. doi: 10.1016/j.jmoldx.2012.01.007. Epub 2012 Apr 9.

PMID:
22490445
2.

IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer.

Spentzos D, Cannistra SA, Grall F, Levine DA, Pillay K, Libermann TA, Mantzoros CS.

Endocr Relat Cancer. 2007 Sep;14(3):781-90.

3.

Validating the impact of a molecular subtype in ovarian cancer on outcomes: a study of the OVCAD Consortium.

Pils D, Hager G, Tong D, Aust S, Heinze G, Kohl M, Schuster E, Wolf A, Sehouli J, Braicu I, Vergote I, Cadron I, Mahner S, Hofstetter G, Speiser P, Zeillinger R.

Cancer Sci. 2012 Jul;103(7):1334-41. doi: 10.1111/j.1349-7006.2012.02306.x. Epub 2012 May 17.

4.

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.

Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I; Australian Ovarian Cancer Study Group, Gertig D, DeFazio A, Bowtell DD.

Clin Cancer Res. 2008 Aug 15;14(16):5198-208. doi: 10.1158/1078-0432.CCR-08-0196.

5.

Unique gene expression profile based on pathologic response in epithelial ovarian cancer.

Spentzos D, Levine DA, Kolia S, Otu H, Boyd J, Libermann TA, Cannistra SA.

J Clin Oncol. 2005 Nov 1;23(31):7911-8. Epub 2005 Oct 3.

PMID:
16204010
6.

Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling.

Gilks CB, Vanderhyden BC, Zhu S, van de Rijn M, Longacre TA.

Gynecol Oncol. 2005 Mar;96(3):684-94.

PMID:
15721412
7.

Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.

Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, Frumovitz M, Atkinson EN, Smith DI, Hartmann L, Fishman D, Berchuck A, Whitaker R, Gershenson DM, Mills GB, Bast RC Jr, Lu KH.

Clin Cancer Res. 2005 Sep 1;11(17):6116-26.

8.

Identification of genes associated with ovarian cancer metastasis using microarray expression analysis.

Lancaster JM, Dressman HK, Clarke JP, Sayer RA, Martino MA, Cragun JM, Henriott AH, Gray J, Sutphen R, Elahi A, Whitaker RS, West M, Marks JR, Nevins JR, Berchuck A.

Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1733-45.

PMID:
17009964
9.

Gene expression profiles as prognostic markers in women with ovarian cancer.

Jochumsen KM, Tan Q, Høgdall EV, Høgdall C, Kjaer SK, Blaakaer J, Kruse TA, Mogensen O.

Int J Gynecol Cancer. 2009 Oct;19(7):1205-13. doi: 10.1111/IGC.0b013e3181a3cf55.

PMID:
19823056
10.

Microarray expression identification of differentially expressed genes in serous epithelial ovarian cancer compared with bulk normal ovarian tissue and ovarian surface scrapings.

Grisaru D, Hauspy J, Prasad M, Albert M, Murphy KJ, Covens A, Macgregor PF, Rosen B.

Oncol Rep. 2007 Dec;18(6):1347-56.

PMID:
17982616
11.

Association between glutathione-S-transferase GSTP1 genotypes, GSTP1 over-expression, and outcome in epithelial ovarian cancer.

Howells RE, Dhar KK, Hoban PR, Jones PW, Fryer AA, Redman CW, Strange RC.

Int J Gynecol Cancer. 2004 Mar-Apr;14(2):242-50.

PMID:
15086723
12.

Gene-expression profiling in epithelial ovarian cancer.

Konstantinopoulos PA, Spentzos D, Cannistra SA.

Nat Clin Pract Oncol. 2008 Oct;5(10):577-87. doi: 10.1038/ncponc1178. Epub 2008 Jul 22. Review.

PMID:
18648354
13.

Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.

Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, Barrett JC, Boyd J, Birrer MJ.

Clin Cancer Res. 2005 Sep 15;11(18):6422-30.

14.

BTF4/BTNA3.2 and GCS as candidate mRNA prognostic markers in epithelial ovarian cancer.

Le Page C, Ouellet V, Quinn MC, Tonin PN, Provencher DM, Mes-Masson AM.

Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):913-20. doi: 10.1158/1055-9965.EPI-07-0692.

15.

An apoptotic molecular network identified by microarray: on the TRAIL to new insights in epithelial ovarian cancer.

Ouellet V, Le Page C, Madore J, Guyot MC, Barrès V, Lussier C, Tonin PN, Provencher DM, Mes-Masson AM.

Cancer. 2007 Jul 15;110(2):297-308.

16.

Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.

Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ.

Cancer Res. 2005 Nov 15;65(22):10602-12.

17.
18.

Biomarker discovery in epithelial ovarian cancer by genomic approaches.

Mok SC, Elias KM, Wong KK, Ho K, Bonome T, Birrer MJ.

Adv Cancer Res. 2007;96:1-22. Review.

PMID:
17161674
19.

Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.

Ramalingam P.

Oncology (Williston Park). 2016 Feb;30(2):166-76. Review.

20.

Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.

Shigemasa K, Tian X, Gu L, Tanimoto H, Underwood LJ, O'Brien TJ, Ohama K.

Oncol Rep. 2004 Jun;11(6):1153-9.

PMID:
15138549

Supplemental Content

Support Center